Introduction
Prostate cancer is the most common malignancy among men worldwide. 1 In addition, the incidence of prostate cancer has increased significantly in most Asian populations. 2 There has been a lot of progress in the therapeutic options including novel molecularly targeted therapeutics for prostate cancer patients in the past decade. 3, 4 Over the past decade, many clinical or experimental studies have provided many fundamental insights into the pathogenesis of prostate cancer. [5] [6] [7] There are a number of risk factors for prostate cancer reported in published literatures, such as vasectomy and alcohol intake. [8] [9] [10] However, there is still limited number of modifiable risk factors identified for prostate cancer and more studies are needed to identify some modifiable risk factors associated with prostate cancer.
The roles of vitamin D in human diseases have received increased attention, and it has been regarded as a vital hormone to maintain the normal functions of various submit your manuscript | www.dovepress.com
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gao et al organs or systems in the bodies. [11] [12] [13] [14] Vitamin D has some extraskeletal biological functions including inhibiting the progression of cancer cells. 15, 16 A previous study has found that vitamin D can exert a key role in decreasing cancer risk. 17 Meta-analyses of epidemiological studies have suggested that higher circulating 25-hydroxyvitamin D (25[OH]D) concentration is correlated with decreased risks of several common cancers, such as colorectal cancer and bladder cancer. 18, 19 Considering the preventive effect of vitamin D against cancer, many researchers also studied the association of circulating 25 [OH]D concentration with prostate cancer. [20] [21] [22] [23] [24] [25] [26] [27] [28] Some studies reported that higher serum 25 For the dose-response meta-analysis, the number of cases and noncases, concentration level, and adjusted RR for each category and its 95% confidence interval (CI) were extracted. For the studies that did not provide the median or mean levels of serum 25 [OH]D, we used the midpoint of each category as the alternative. For the open-ended category, the midpoint of this category was calculated by assuming that the interval was the same as that of the adjacent category. When the numbers of cases/noncases in each category were not available, the numbers were estimated by the methods proposed by Aune et al. 31 For studies that did not set the lowest category as reference, we used the method described by Hamling et al 32 to make a transformation. Furthermore, we gathered information on study design, country, sample size, matching factors, and time of follow-up or from blood collection to diagnosis. Studies with .300 prostate cancer cases were defined as studies with large sample size, while those with ,300 prostate cancer cases were defined as studies with small sample size. The quality assessment was done by the recommendation from Newcastle-Ottawa Scale (NOS), which encompassed three perspectives including selection of participants, comparability, and outcome assessment, and studies scoring at least 6 stars were classified as highquality studies. 33 
statistical analysis
The homogeneity among those included studies was estimated by the I 2 statistic, and I
2
.50% represented high concentration of heterogeneity. 34 A random-effect metaanalysis was first done to calculate the summary RR and 95% CI comparing the higher concentration with the lower concentration of 25 [OH]D. 35 The dose-response metaanalysis was performed using the method proposed by Greenland and Longnecker 36 and Orsini et al. 37 In order to explore the nonlinear dose-response curve, serum 25 [OH]D concentrations were modeled using restricted cubic splines with three knots at fixed percentiles (0.10, 0.50, and 0.90) of the distribution. The P-value of nonlinearity was calculated by testing against the null hypothesis that the coefficient of the second spline was equal to 0. If the nonlinearity was not statistically significant, the linear dose-response outcomes were presented per 10 ng/mL (25 nmol/L) increment in serum 25 [OH]D by random-effects model. [35] [36] [37] Subgroup analysis was performed by sample size, publication year, study designs, and adjustment for calcium intake. Sensitivity analysis was carried out by excluding any single study by turns. Publication bias was evaluated by funnel plot and the Egger test. 38 The traditional metaanalysis was carried out using STATA (Version 12.0), 
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Circulating vitamin D and prostate cancer risk and the dose-response meta-analysis was performed by R and its dosresmeta package. 39 
Results
Characteristics of included studies
The study selection process is shown in Figure 1 . Though .1,530 articles were found, only 42 studies were possibly eligible and evaluated by checking the full texts. 16, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Twenty-three studies were then excluded, 16, and the remaining 19 studies were considered eligible. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [62] [63] [64] [65] [66] [67] [68] [69] There were three prospective cohort studies and 16 nested case-control studies (Table 1) . Most studies were carried out in Europe and USA except one study from Japan ( (Figure 4 ). The summary RR was not significantly changed in the sensitivity analysis. As shown in Table 2 , subgroup analysis using data from studies of large sample size also found a modest dose-response relationship (RR =1.04, 95% CI 1.02-1.06, P,0.001). However, subgroup analysis using data from studies of small sample size or cohort study design did not find an obvious dose-response relationship (Table 2 ).
• The funnel plot did not detect publication bias ( Figure 5) . Besides, the P-value of Egger test was 0.48 and provided another evidence for the lack of publication bias.
Discussion
Though the preventive roles of vitamin D have been found in several cancers, its role in the development of prostate cancer is still unclear. Those published studies did not report consistent findings. We therefore carried out a doseresponse meta-analysis to quantitatively elucidate the impact of circulating 25 Figure 1 ). Dose-response metaanalysis showed the summary RR of prostate cancer caused by per 10 ng/mL increment was 1.04 (P,0.001; Figure 2) . Therefore, the findings from the meta-analysis suggested that higher 25 [OH]D concentration was correlated with elevated risk of prostate cancer and a modest dose-response effect existed in this association.
In human bodies, vitamin D is mainly synthesized in the skin after exposure to solar UV radiation and vitamin D can also be ingested from some foods. 70, 71 25 [OH]D is the 
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Circulating vitamin D and prostate cancer risk hydroxylated form of vitamin D, which is the mostly used biomarker of circulating vitamin D and widely used in clinical practice. 72 A large number of published studies have found that vitamin D can exert a key role in decreasing cancer risk. [17] [18] [19] [73] [74] [75] The antitumor effects of vitamin D have been well established in several cancers, such as colorectal cancer and bladder cancer. 18, 19 On the contrary, some studies found that vitamin D did not exert an antitumor effect in prostate cancer but even caused elevated risk of prostate cancer. 26, 29, 30 This present meta-analysis of 19 prospective studies provided 
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Circulating vitamin D and prostate cancer risk epidemiological evidence for the tumor-promoting effect of vitamin D in prostate cancer though the effect was modest. However, no clear biological relationship has been found between high levels of vitamin D and an increased risk of prostate cancer. We can only speculate on the cause for the tumor-promoting effect of vitamin D in prostate cancer. 25 One reason might be that 25 [OH]D may be a marker of other factors that related to the risk of prostate cancer. For example, insulin-like growth factor-I (IGF-I) has been related to prostate cancer [76] [77] [78] and a relationship between 25 [OH]D and insulin-like growth factor-1 has been reported. 79 Moreover, higher 25 [OH]D might be associated with an increased detection rate of prostate cancer. 25 However, we cannot rule out this detection bias using the summary outcome from the included studies in our research. The findings in the meta-analysis may have important indications from the supplementation of vitamin D in men. The use of vitamin D in men with high risk of prostate cancer may be cautious considering the tumorpromoting effect of vitamin D in prostate cancer.
A major strength of this meta-analysis was the inclusion of a total of 19 prospective cohort studies or nested case-control studies. The large number of participants in the meta-analysis could help us quantitatively examine the association of circulating 25 [OH]D concentration with prostate cancer and get a more credible finding. As shown in Table 1 , all included studies used a prospective design and reported adjusted RRs of prostate cancer, which ensured the appropriate selection of participants, the correct assessment of outcomes. In addition, there were 12 studies with .300 prostate cancer cases, which could increase the statistical power and decrease the risk of possible bias caused by small sample size (Table 1) . Another strength of this meta-analysis was the good homogeneity among those included studies (I 2 =0%), which suggested the lack of obvious heterogeneity in the meta-analysis. There was good homogeneity in both the meta-analysis of RRs comparing the higher concentration with the lower concentration of 25 [OH]D and the meta-analysis of RRs of prostate cancer risk caused by per 10 ng/mL increment. There is no doubt that the homogeneity could strengthen the evidence for the tumor-promoting effect of vitamin D in prostate cancer found in the meta-analysis.
There were several limitations and the outcomes should be interpreted cautiously. First, some included studies did not consider the influence of other factors, such as vitamin D intake and sun exposure, on the association between circulating 25 [OH]D concentration and prostate cancer, which might cause possible risk of bias. Therefore, more studies taking into account those factors are needed to provide a more definite assessment of the influence of circulating 25 [OH]D concentration on prostate cancer risk. Second, the reagents used to detect circulating 25 [OH]D concentration were various across those included studies, which could cause possible heterogeneity in the meta-analysis. However, there was good homogeneity among those included studies (I 2 =0%), which proved the little influence of different reagents used to detect circulating 25 [OH]D concentration in the meta-analysis. Third, because all the included studies were done in developed countries and most studies were done in the Western countries (northern Europe and USA), the findings could not be generalized to other countries from different ethnicities. There was only one study with small sample size from Asian countries. 28 Participants in the studies that conducted in the USA were mostly white, and only one study with moderate sample size had multiple ethnics. 65 Therefore, more studies assessing the correlation of vitamin D with prostate cancer risk from other ethnicities and developing countries are needed. Finally, results of subgroups were based on a limited number of studies and we cannot rule out the possibility that insufficient statistical power may be present.
Conclusion
The findings from the meta-analysis suggest that higher 25 [OH]D concentration is correlated with elevated risk of prostate cancer and a modest dose-response effect exists. Besides, these results need to be validated in further studies. The biological explanation for the positive correlation of vitamin D with prostate cancer risk is unclear, and further research is needed to address this issue.
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